Ortho-McNeil, J&J and Cellzome, BSI Proteomics, Boehringer Ingelheim and MorphoSys, Proteome Systems, Biacore International, Teranode and St. Jude, Luminex, NIEHS, and Bruker BioSciences | GenomeWeb

Ortho-McNeil, J&J to Use Cellzome Proteomics Tech in Alzheimer’s Research Program

Cellzome last week said that it will collaborate with Johnson & Johnson Pharmaceutical Research & Development, an affiliate of Ortho-McNeil Pharmaceutical, in a drug-discovery research program for Alzheimer’s disease.

Cellzome will apply its chemical proteomics technology to the program, and will receive a technology-access fee and research funding for two years. The company said it is also eligible for development milestone payments.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: intellectual property landscape of CRISPR genome editing, and more.

A researcher has been convicted of conspiring to steal genetically engineered rice, Reuters reports.

Harvard Medical School's George Church says a woolly mammoth-elephant hybrid is only a few years away, according to the New Scientist.

Intel is ending its sponsorship of the International Science and Engineering Fair, the New York Times reports.